Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment.

ABSTRACT:

Background

Ovarian cancer is the deadliest gynecologic malignancy despite current first-line treatment with a platinum and taxane doublet. Artesunate has broad antineoplastic properties but has not been investigated in combination with carboplatin and paclitaxel for ovarian cancer treatment.

Methods

Standard cell culture technique with commercially available ovarian cancer cell lines were utilized in cell viability, DNA damage, and cell cycle progression assays to qualify and quantify artesunate treatment effects. Additionally, the sequence of administering artesunate in combination with paclitaxel and carboplatin was determined. The activity of artesunate was also assessed in 3D organoid models of primary ovarian cancer and RNAseq analysis was utilized to identify genes and

SUBMITTER: McDowell A 

PROVIDER: S-EPMC7996621 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature